Artificial intelligence and machine-learning approaches in structure and ligand-based discovery of drugs affecting central nervous system

CNS disorders are indications with a very high unmet medical needs, relatively smaller number of available drugs, and a subpar satisfaction level among patients and caregiver. Discovery of CNS drugs is extremely expensive affair with its own unique challenges leading to extremely high attrition rate...

Full description

Saved in:
Bibliographic Details
Published in:Molecular diversity 2023-04, Vol.27 (2), p.959-985
Main Authors: Gautam, Vertika, Gaurav, Anand, Masand, Neeraj, Lee, Vannajan Sanghiran, Patil, Vaishali M.
Format: Article
Language:English
Subjects:
Artificial Intelligence
Biochemistry
Biomedical and Life Sciences
Central Nervous System
Comprehensive Review
Humans
Life Sciences
Ligands
Machine Learning
Organic Chemistry
Pharmacy
Polymer Sciences
Proteomics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:CNS disorders are indications with a very high unmet medical needs, relatively smaller number of available drugs, and a subpar satisfaction level among patients and caregiver. Discovery of CNS drugs is extremely expensive affair with its own unique challenges leading to extremely high attrition rates and low efficiency. With explosion of data in information age, there is hardly any aspect of life that has not been touched by data driven technologies such as artificial intelligence (AI) and machine learning (ML). Drug discovery is no exception, emergence of big data via genomic, proteomic, biological, and chemical technologies has driven pharmaceutical giants to collaborate with AI oriented companies to revolutionise drug discovery, with the goal of increasing the efficiency of the process. In recent years many examples of innovative applications of AI and ML techniques in CNS drug discovery has been reported. Research on therapeutics for diseases such as schizophrenia, Alzheimer’s and Parkinsonism has been provided with a new direction and thrust from these developments. AI and ML has been applied to both ligand-based and structure-based drug discovery and design of CNS therapeutics. In this review, we have summarised the general aspects of AI and ML from the perspective of drug discovery followed by a comprehensive coverage of the recent developments in the applications of AI/ML techniques in CNS drug discovery. Graphical abstract
ISSN:1381-1991
1573-501X
DOI:10.1007/s11030-022-10489-3